Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective

被引：0
|
作者：
Marc Evans
Jens Gundgaard
Brian Bekker Hansen
机构：
[1] University Hospital Llandough,
[2] Global Market Access,undefined
[3] Novo Nordisk A/S,undefined
来源：
Diabetes Therapy | 2016年 / 7卷
关键词：
Cost-effectiveness; Insulin analogs; Pharmacoeconomics; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：809 / 823
页数：14
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of insulin therapy in type 2 diabetes patients comparing biphasic insulin aspart 70/30 versus insulin plargine in the Swedish setting
    Ray, Joshua A.
    Munro, Vicki
    Brandt, Ann-Sofie
    Valentine, William J.
    Roze, Stephane
    Foos, Volker
    Lurati, Francesco
    Palmer, Andrew J.
    [J]. DIABETES, 2006, 55 : A558 - A558
  • [22] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30
    Vaag, A.
    Leiter, L. A.
    Franek, E.
    Weng, J.
    Damci, T.
    Munoz Torres, M.
    Donnet, J. -P.
    Endahl, L.
    Skjoth, T.
    Niskanen, L.
    [J]. DIABETOLOGIA, 2011, 54 : S423 - S423
  • [23] Evaluating the cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for the treatment of type 2 diabetes in a Spanish setting
    Tucker, D.
    Valentine, W. J.
    Nielsen, S.
    Townsend, C.
    Kotchie, R.
    Scheijbeler, H.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A263 - A263
  • [24] Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea
    Lee, Kyoung Hee
    Seo, Se Jin
    Smith-Palmer, Jayne
    Palmer, James L.
    White, Jeremy
    Valentine, William J.
    [J]. VALUE IN HEALTH, 2009, 12 : S55 - S61
  • [25] Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
    Niskanen, Leo
    Leiter, Lawrence A.
    Franek, Edward
    Weng, Jianping
    Damci, Taner
    Munoz-Torres, Manuel
    Donnet, Jean-Paul
    Endahl, Lars
    Skjoth, Trine Vang
    Vaag, Allan
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 167 (02) : 287 - 294
  • [26] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY VERSUS BASAL-BOLUS FULL REGIMEN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ALGERIA
    Sellam, Y.
    Malek, R.
    Semrouni, M.
    Belhadj, M.
    Zekri, S.
    Brouri, M.
    Arbouche, Z.
    Nouri, N.
    [J]. VALUE IN HEALTH, 2020, 23 : S511 - S511
  • [27] Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China
    Palmer, James L.
    Gibbs, Meaghan
    Scheijbeler, Huib W. K. F. H.
    Kotchie, Robert W.
    Nielsen, Steffen
    White, Jeremy
    Valentine, William J.
    [J]. ADVANCES IN THERAPY, 2008, 25 (08) : 752 - 774
  • [28] Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes
    Lindholm, A
    Jensen, LB
    Home, PD
    Raskin, P
    Boehm, BO
    Råstam, J
    [J]. DIABETES CARE, 2002, 25 (05) : 876 - 882
  • [29] Biphasic insulin aspart and biphasic human insulin in type 2 diabetes: A comparison
    Jacobsen, LV
    Bell, PM
    McSorely, P
    Kristensen, A
    [J]. DIABETES, 2000, 49 : A112 - A112
  • [30] Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective
    Evans, M.
    Wolden, M.
    Gundgaard, J.
    Chubb, B.
    Christensen, T.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (04): : 366 - 375
12345